Trial · NCT03280030
Results by group103
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 103
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Safety Events (Part 1, Japan Only) | Midostaurin: Part 1 (Japan Only) | Experienced at least 1 adverse event (AE) | 5 | Participants | |
| Percentage of Safety Events (Part 1, Japan Only) | Midostaurin: Part 1 (Japan Only) | Safety events determined by ISC related to midostaurin (n = 3, 0, 0) | 0 | Participants | |
| Event Free Survival (EFS) (Part 2 - Randomized, Controlled) | Midostaurin: Part 2 | 7.6 | 95% Confidence Interval 3.6 to NA | Months | |
| Event Free Survival (EFS) (Part 2 - Randomized, Controlled) | Placebo: Part 2 | NA | 95% Confidence Interval 8.2 to NA | Months | |
| Overall Survival | Midostaurin: Part 2 | NA | 95% Confidence Interval 16.8 to NA | Months | |
| Overall Survival | Placebo: Part 2 | NA | 95% Confidence Interval 18.8 to NA | Months | |
| Percentage of Participants With Complete Remission (CR) | Midostaurin: Part 2 | Overall CR | 70.0 | 95% Confidence Interval 50.60 to 85.27 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Placebo: Part 2 | Overall CR | 78.1 | 95% Confidence Interval 60.03 to 90.72 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Midostaurin: Part 2 | Morphologic CR with incomplete platelet count recovery (CRp) | 6.7 | 95% Confidence Interval 0.86 to 22.07 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Placebo: Part 2 | Morphologic CR with incomplete platelet count recovery (CRp) | 0.0 | 95% Confidence Interval 0.00 to 10.89 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Midostaurin: Part 2 | End of Induction cycle 1 (C1) CR | 56.7 | 95% Confidence Interval 37.43 to 74.54 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Placebo: Part 2 | End of Induction cycle 1 (C1) CR | 65.6 | 95% Confidence Interval 46.81 to 81.43 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Midostaurin: Part 2 | End of Induction C1: Morphologic CRp | 3.3 | 95% Confidence Interval 0.08 to 17.22 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Placebo: Part 2 | End of Induction C1: Morphologic CRp | 0.0 | 95% Confidence Interval 0.00 to 10.89 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Midostaurin: Part 2 | End of Induction cycle 2 (C2) CR | 13.3 | 95% Confidence Interval 3.76 to 30.72 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Placebo: Part 2 | End of Induction cycle 2 (C2) CR | 9.4 | 95% Confidence Interval 1.98 to 25.02 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Midostaurin: Part 2 | End of Induction C2: Morphologic CRp | 3.3 | 95% Confidence Interval 0.08 to 17.00 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Placebo: Part 2 | End of Induction C2: Morphologic CRp | 0.0 | 95% Confidence Interval 0.00 to 10.89 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Midostaurin: Part 2 | End of Consolidation CR | 36.7 | 95% Confidence Interval 19.93 to 56.14 | Percentage of participants |
| Percentage of Participants With Complete Remission (CR) | Placebo: Part 2 | End of Consolidation CR | 43.8 | 95% Confidence Interval 26.36 to 62.34 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03280030/results